Old Well Partners, LLC I Mab Transaction History

Old Well Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $9,924 - $22,116	-1,200 Reduced 0.95%	125,325 $1.42 Million
Q1 2022 May 16, 2022	BUY	$12.54 - $46.93 $303,468 - $1.14 Million	24,200 Added 23.65%	126,525 $2.06 Million
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $2.61 Million - $4.29 Million	-57,575 Reduced 36.01%	102,325 $4.85 Million
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $857,700 - $1.27 Million	15,000 Added 10.35%	159,900 $11.6 Million
Q2 2021 Aug 16, 2021	BUY	$47.86 - $83.95 $6.93 Million - $12.2 Million	144,900 New	144,900 $12.2 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $77.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Old Well Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Old Well Partners, LLC with notifications on news.